HC Wainwright reissued their buy rating on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research report report published on Monday, Stock Target Advisor reports. The firm currently has a $26.00 price target on the stock.
Several other research firms have also recently weighed in on IMUX. SVB Leerink dropped their price objective on Immunic from $45.00 to $9.00 and set an outperform rating for the company in a report on Friday, June 3rd. Wedbush dropped their price objective on Immunic from $61.00 to $14.00 in a report on Thursday, June 2nd. Finally, Aegis dropped their price objective on Immunic from $40.00 to $35.00 and set a buy rating for the company in a report on Monday, August 8th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $24.60.
Immunic Stock Performance
NASDAQ IMUX opened at $3.85 on Monday. Immunic has a fifty-two week low of $2.52 and a fifty-two week high of $14.50. The stock has a 50 day simple moving average of $4.39 and a two-hundred day simple moving average of $6.30. The stock has a market cap of $117.68 million, a P/E ratio of -1.27 and a beta of 1.98.
Institutional Inflows and Outflows
Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.
- Get a free copy of the StockNews.com research report on Immunic (IMUX)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.